Indivior Pharmaceuticals, Inc.

Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder

Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th

Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th  

Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering

Indivior Announces Proposed Convertible Senior Notes Offering